Literature DB >> 22166890

Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development.

Kazuhiko Hanada1, Kenya Nakai, Hiromasa Tanaka, Fumitaka Suzuki, Hiromitsu Kumada, Yasuo Ohno, Shogo Ozawa, Hiroyasu Ogata.   

Abstract

Analysis of mRNAs from liver biopsy samples of patients with chronic hepatitis C revealed that the levels of nuclear receptor expression were correlated with those of drug-metabolizing enzymes and transporters in relation to the development of fibrosis. Overall, the median mRNA level was largely dependent on fibrosis stage (F), and that for stage 3 patients (F3) was about 50% less than that for F1 patients. Levels of expression of AhR, together with CAR and PXR, were lowest in livers of F3 patients. Multivariate linear regression analysis revealed that AhR expression appeared to be involved in the regulation of CYP1A2, 2E1, 2D6, UGT1A, MDR1/3, MRP2/3, NTCP and OCT1 in the livers of patients with chronic hepatitis C. These results suggest that downregulation of AhR during the progression of liver fibrosis is associated with decreased expression levels of these phase I and II enzymes and drug transporters during inflammation-related signal transduction between AhR and other nuclear receptors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22166890     DOI: 10.2133/dmpk.dmpk-11-rg-077

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  16 in total

1.  Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.

Authors:  Brian C Ferslew; Kathleen Köck; Arlene S Bridges; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2014-06-23       Impact factor: 3.922

2.  Expression of P450 and nuclear receptors in normal and end-stage Chinese livers.

Authors:  Hong Chen; Zhong-Yang Shen; Wang Xu; Tie-Yan Fan; Jun Li; Yuan-Fu Lu; Ming-Liang Cheng; Jie Liu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 3.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics.

Authors:  Sarah Billington; Adrian S Ray; Laurent Salphati; Guangqing Xiao; Xiaoyan Chu; W Griffith Humphreys; Mingxiang Liao; Caroline A Lee; Anita Mathias; Cornelis E C A Hop; Christopher Rowbottom; Raymond Evers; Yurong Lai; Edward J Kelly; Bhagwat Prasad; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2017-11-14       Impact factor: 3.922

Review 5.  Effect of Liver Disease on Hepatic Transporter Expression and Function.

Authors:  Nilay Thakkar; Jason R Slizgi; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2017-04-30       Impact factor: 3.534

Review 6.  Withaferin A in the Treatment of Liver Diseases: Progress and Pharmacokinetic Insights.

Authors:  Yangliu Xia; Mingrui Yan; Ping Wang; Keisuke Hamada; Nana Yan; Haiping Hao; Frank J Gonzalez; Tingting Yan
Journal:  Drug Metab Dispos       Date:  2021-12-13       Impact factor: 3.579

Review 7.  Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters.

Authors:  M Sawkat Anwer; Bruno Stieger
Journal:  Pflugers Arch       Date:  2013-10-03       Impact factor: 3.657

8.  Importance of detoxifying enzymes in differentiating fibrotic development between SHRSP5/Dmcr and SHRSP rats.

Authors:  Hisao Naito; Xiaofang Jia; Husna Yetti; Yukie Yanagiba; Hazuki Tamada; Kazuya Kitamori; Yumi Hayashi; Dong Wang; Masashi Kato; Akira Ishii; Tamie Nakajima
Journal:  Environ Health Prev Med       Date:  2016-05-21       Impact factor: 3.674

Review 9.  Nuclear receptors as drug targets in cholestatic liver diseases.

Authors:  Emina Halilbasic; Anna Baghdasaryan; Michael Trauner
Journal:  Clin Liver Dis       Date:  2013-05       Impact factor: 6.126

10.  Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir.

Authors:  Hayato Baba; Kazuto Tajiri; Kohei Nagata; Kengo Kawai; Masami Minemura; Toshiro Sugiyama
Journal:  Case Rep Gastroenterol       Date:  2016-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.